Recent experimental data indicate that gefitinib can restore sensitivity to topotecan in multidrug-resistant NSCLC cells overexpressing the breast cancer resistance protein (BCRP) (Nagashima et al, 2006). Here, ABCG2 is linked to non-small cell lung carcinoma.